AU2007325029B2 - Methods for treating and diagnosing fibrotic and fibroproliferative diseases - Google Patents

Methods for treating and diagnosing fibrotic and fibroproliferative diseases Download PDF

Info

Publication number
AU2007325029B2
AU2007325029B2 AU2007325029A AU2007325029A AU2007325029B2 AU 2007325029 B2 AU2007325029 B2 AU 2007325029B2 AU 2007325029 A AU2007325029 A AU 2007325029A AU 2007325029 A AU2007325029 A AU 2007325029A AU 2007325029 B2 AU2007325029 B2 AU 2007325029B2
Authority
AU
Australia
Prior art keywords
subject
circulating
fibrocytes
fibrotic
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007325029A
Other languages
English (en)
Other versions
AU2007325029A1 (en
Inventor
John A. Belperio
Marie D. Burdick
Michael P. Keane
Borna Mehrad
Robert M. Strieter
David A. Zisman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of California, San Diego
Original Assignee
University of Virginia Patent Foundation
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation, University of California Berkeley, University of California, San Diego filed Critical University of Virginia Patent Foundation
Publication of AU2007325029A1 publication Critical patent/AU2007325029A1/en
Application granted granted Critical
Publication of AU2007325029B2 publication Critical patent/AU2007325029B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007325029A 2006-11-30 2007-11-30 Methods for treating and diagnosing fibrotic and fibroproliferative diseases Ceased AU2007325029B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87201906P 2006-11-30 2006-11-30
US60/872,019 2006-11-30
PCT/US2007/086167 WO2008067559A2 (en) 2006-11-30 2007-11-30 Methods for treating and diagnosing fibrotic and fibroproliferative diseases

Publications (2)

Publication Number Publication Date
AU2007325029A1 AU2007325029A1 (en) 2008-06-05
AU2007325029B2 true AU2007325029B2 (en) 2013-09-12

Family

ID=39468768

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007325029A Ceased AU2007325029B2 (en) 2006-11-30 2007-11-30 Methods for treating and diagnosing fibrotic and fibroproliferative diseases

Country Status (5)

Country Link
US (2) US8114608B2 (enExample)
EP (1) EP2100140B1 (enExample)
JP (1) JP5296701B2 (enExample)
AU (1) AU2007325029B2 (enExample)
WO (1) WO2008067559A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5380287B2 (ja) 2006-07-18 2014-01-08 ノクソン・ファルマ・アクチエンゲゼルシャフト Ｓｄｆ−１結合核酸
PT2190991T (pt) * 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
CA2745027A1 (en) * 2008-10-22 2010-04-29 Allocure, Inc. Methods of using sdf-1 (cxcl12) as a diagnostic and mesenchymal stem cell (multipotent stromal cell)-specific therapeutic biomarker for the treatment of kidney injury and other major organs
JP2012127879A (ja) * 2010-12-16 2012-07-05 Kanazawa Univ 腎症の進行度の判定方法並びに線維化抑制剤。
CN103376228B (zh) * 2012-04-27 2016-02-17 中国人民解放军军事医学科学院放射与辐射医学研究所 一种检测或辅助检测放射性肺纤维化的试剂盒
US9952202B2 (en) * 2013-03-14 2018-04-24 Galapagos Nv Methods of identifying compounds for the treatment of fibrosis by using S1PR5
JP6601707B2 (ja) * 2015-02-15 2019-11-06 国立大学法人金沢大学 線維化判定方法
JP7126668B2 (ja) * 2017-08-09 2022-08-29 国立大学法人金沢大学 膠原病判定方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238620A1 (en) * 2002-12-23 2005-10-27 Richard Gomer Compositions and methods for suppressing fibrocyte differentiation from monocytes and for detecting fibrocyte differentiation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759036B1 (en) * 1997-03-28 2004-07-06 The Picower Institute For Medical Research Fibrocyte-base vaccine formulations
US8293479B2 (en) * 2002-05-02 2012-10-23 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238620A1 (en) * 2002-12-23 2005-10-27 Richard Gomer Compositions and methods for suppressing fibrocyte differentiation from monocytes and for detecting fibrocyte differentiation

Also Published As

Publication number Publication date
WO2008067559A2 (en) 2008-06-05
AU2007325029A1 (en) 2008-06-05
US20120094305A1 (en) 2012-04-19
US8114608B2 (en) 2012-02-14
US20100074887A1 (en) 2010-03-25
JP2010511389A (ja) 2010-04-15
US8216796B2 (en) 2012-07-10
EP2100140A4 (en) 2010-07-21
EP2100140A2 (en) 2009-09-16
WO2008067559A3 (en) 2008-07-17
JP5296701B2 (ja) 2013-09-25
EP2100140B1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
US8216796B2 (en) Methods for treating and diagnosing fibrotic and fibroproliferative diseases
AU2008207533B2 (en) Methods for diagnosis and treatment of epithelial-derived cancers
US9359402B2 (en) EphA2 T-cell epitope agonists and uses therefore
Chen et al. The significance of titin antibodies in myasthenia gravis: correlation with thymoma and severity of myasthenia gravis
US20100055723A1 (en) Galectin-3-Binding Protein as a Biomarker of Cardiovascular Disease
AU2011315938B2 (en) Biomarker and Method for Detecting a Chronic Inflammatory-Associated Disease
WO2011157905A1 (en) Polyclonal antibody binding to acetylated hmgb1
CN102958530B (zh) 通过ccr6阻断ccl18信号转导作为纤维化疾病和癌症的治疗选择
US20090004183A1 (en) Compositions and Methods for Regulating the Alternative Pathway of Complement
HUP0200777A2 (en) Method of diagnosing transmissible spongiform encephalopathies
US20220242964A1 (en) Compositions and methods for regulating erythropoiesis
WO2013107826A2 (en) Use of cellular biomarkers expression to diagnose sepsis among intensive care patients
EP3938787B1 (en) AUTOANTBODIES USED AS A BIOMARKER FOR PARANEOPLICAL ENCEPHALITIS ASSOCIATED WITH TESTICULAR CANCER
AU2007313151A1 (en) Compositions and methods for modulating TLR14 activity
US9945843B2 (en) Methods for identifying compounds that inhibit G protein-coupled receptor (GPR84) agonist-stimulated chemotaxis
US20090220487A1 (en) Methods and Compositions for Inhibition of Vascular Permeability
US20140377883A1 (en) Peripherin-specific autoantibodies as a marker for neurological and endocrinological disease
CA2676962C (en) Mcam modulation and uses thereof in the management of neuroinflammatory conditions
KR20080085923A (ko) 백혈구 기능 저해를 위한 조성물 및 방법
Dong Investigation of TSG-6 as a Potential Biomarker and Therapeutic Target in Osteoarthritis
WO2016191814A1 (en) Methods and products for enriching and isolating stem cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired